Idenix Pharmaceuticals LLC

( )
IDIX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.31%163.360.7%$1395.05m
PFEPfizer Inc. -0.03%33.790.9%$1240.93m
BMYBristol-Myers Squibb Co. -0.39%61.811.0%$872.49m
MRKMerck & Co., Inc. -0.04%74.550.7%$835.06m
ABBVAbbVie, Inc. -0.09%107.301.9%$808.30m
LLYEli Lilly & Co. -0.32%203.041.1%$779.17m
AZNAstraZeneca Plc 0.59%49.201.2%$523.20m
GSKGlaxoSmithKline Plc -0.38%34.250.2%$269.38m
NVSNovartis AG 0.77%87.440.2%$192.32m
SNYSanofi 1.22%46.360.2%$170.49m
VTRSViatris, Inc. -1.53%14.820.0%$142.10m
VERUVeru, Inc. -3.29%13.810.0%$115.05m
CVACCureVac NV 1.33%94.210.0%$107.67m
VYNEVYNE Therapeutics, Inc. -1.90%7.740.0%$98.29m
NVONovo Nordisk A/S 0.15%72.450.1%$93.17m

Company Profile

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the Company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. The Company has also developed products and drug candidates for the treatment of hepatitis B virus (HBV), human immunodeficiency virus type I (HIV) and acquired immune deficiency syndrome (AIDS).